Cost-effectiveness of adalimumab for early-stage Dupuytren’s disease: an economic evaluation based on a randomized controlled trial and individual-patient simulation model

類似資料

• Cost-effectiveness of adalimumab for early-stage Dupuytren’s disease <subtitle>an economic evaluation based on a randomized controlled trial and individual-patient simulation model</subtitle>
  著者:: Helen Dakin, 等
  出版事項: (2022-11-01)
• What do we know about managing Dupuytren’s Disease cost-effectively?
  著者:: Dritsaki, M, 等
  出版事項: (2018)
• What do we know about managing Dupuytren’s disease cost-effectively?
  著者:: Melina Dritsaki, 等
  出版事項: (2018-01-01)
• Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
  著者:: Nanchahal, J, 等
  出版事項: (2022)
• Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD)
  著者:: Png, M, 等
  出版事項: (2019)